Clinical Trials Directory

Trials / Completed

CompletedNCT06469541

Clinical Outcomes After Implantation of a Monofocal Hydrophobic IOL, Bi-Flex 877PAY With POB-MA Preloaded Injector

Clinical Outcomes After Implantation of a Monofocal Hydrophobic IOL, Bi-Flex 877PAY With POB-MA Preloaded Injector: Visual Outcomes, Refractive Stability, Safety Features, YAG Capsulotomy Rate. (Retrospective Review)

Status
Completed
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Medicontur Medical Engineering Ltd · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of our investigation is to retrospectively assess visual outcomes, refractive stability, safety features of the lens and the incidence of developing PCO (posterior capsular opacification) in a 12-month period following mono- or bilateral implantation of the hydrophobic acrylic monofocal IOL, Bi-Flex 877PAY (Medicontur).

Detailed description

The purpose of our investigation is to retrospectively assess visual outcomes, refractive stability, safety features of the lens and the incidence of developing PCO (posterior capsular opacification) in a 12-month period following mono- or bilateral implantation of the hydrophobic acrylic monofocal IOL, Bi-Flex 877PAY (Medicontur). * Primary objective: o To evaluate the monocular Uncorrected Distance Visual Acuity (UCDVA) 1 year after IOL implantation * Secondary objectives: * To evaluate the spherical equivalent refraction one month postoperatively. * To evaluate level of astigmatism one month postoperatively. * To evaluate the Uncorrected Distance Visual Acuity (UDVA) monocular at 1 day, 1 month and 6 months after IOL implantation * To evaluate the Best Corrected Distance Visual Acuity (CDVA) monocular at 1 month, 6 months and 1 year after IOL implantation * To evaluate safety features of the lens * To evaluate PCO development, Nd:YAG capsulotomy rate

Conditions

Timeline

Start date
2023-04-11
Primary completion
2023-07-31
Completion
2023-12-01
First posted
2024-06-21
Last updated
2024-06-21

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT06469541. Inclusion in this directory is not an endorsement.